Validation of an HPLC Method for the Simultaneous Quantification of Metabolic Reaction Products Catalysed by CYP2C11 Enzymes in Rat Liver Microsomes: In Vitro Inhibitory Effect of Salicylic Acid on CYP2C11 Enzyme.
Animals
Aryl Hydrocarbon Hydroxylases
/ antagonists & inhibitors
Catalysis
Chromatography, High Pressure Liquid
Cytochrome P-450 Enzyme Inhibitors
/ chemistry
Cytochrome P450 Family 2
/ antagonists & inhibitors
Drug Development
Humans
Liver
/ drug effects
Rats
Salicylic Acid
/ chemistry
Steroid 16-alpha-Hydroxylase
/ antagonists & inhibitors
16α-hydroxytestosterone
HPLC
cytochrome P450
phenacetin
salicylic acid
testosterone
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
25 Nov 2019
25 Nov 2019
Historique:
received:
01
10
2019
revised:
19
11
2019
accepted:
20
11
2019
entrez:
29
11
2019
pubmed:
30
11
2019
medline:
18
4
2020
Statut:
epublish
Résumé
The inhibitory effect of new chemical entities on rat liver P450 marker activities was investigated in a functional approach towards drug development. Treatment of colorectal cancer (CRC) and chemoprevention using salicylic acid has gained a lot of attention, mainly in the prevention of the onset of colon cancer. Thus, an in vitro inhibitory effect of salicylic acid on rat CYP2C11 activity was examined by using high performance liquid chromatography (HPLC). High performance liquid chromatography analysis of a CYP2C11 assay was developed on a reversed phase C
Identifiants
pubmed: 31775347
pii: molecules24234294
doi: 10.3390/molecules24234294
pmc: PMC6930622
pii:
doi:
Substances chimiques
Cytochrome P-450 Enzyme Inhibitors
0
Aryl Hydrocarbon Hydroxylases
EC 1.14.14.1
CYP2C11 protein, rat
EC 1.14.14.1
Cytochrome P450 Family 2
EC 1.14.14.1
Steroid 16-alpha-Hydroxylase
EC 1.14.14.1
Salicylic Acid
O414PZ4LPZ
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Déclaration de conflit d'intérêts
The authors declare no conflict of financial interest or any financial involvement with any company.
Références
Pharmacol Ther. 2013 Apr;138(1):103-41
pubmed: 23333322
Asian Pac J Cancer Prev. 2018 Aug 24;19(8):2057-2070
pubmed: 30139042
Pharmacol Rep. 2013;65(5):1247-55
pubmed: 24399720
Perfusion. 2008 Nov;23(6):309
pubmed: 19454558
Br J Clin Pharmacol. 1998 Feb;45(2):107-14
pubmed: 9491822
Fitoterapia. 2014 Jan;92:1-8
pubmed: 24144799
J Pharm Biomed Anal. 2017 May 10;138:109-117
pubmed: 28192718
Biochem Mol Biol Educ. 2006 Mar;34(2):66-74
pubmed: 21638641
J Pharmacol Toxicol Methods. 1997 Mar;37(2):67-73
pubmed: 9174981
J Adv Pract Oncol. 2013 Jul;4(4):263-8
pubmed: 25032007
J Appl Toxicol. 2009 Jul;29(5):435-45
pubmed: 19391105
Chem Biol Interact. 2010 Feb 12;183(3):363-8
pubmed: 19948161
Cancer Res. 2001 May 1;61(9):3566-9
pubmed: 11325819
Am Fam Physician. 2007 Aug 1;76(3):391-6
pubmed: 17708140